COMMON STOCK PURCHASE AGREEMENT
This COMMON STOCK PURCHASE AGREEMENT (this "Agreement") is dated as of November 1, 1999
by and between Nymox Pharmaceutical Corporation, a Canada corporation (the "Company"), and Jaspas
Investments Limited (the "Purchaser").
The parties hereto agree as follows:
Section 1.1 Certain Definitions.
(a) "Average Daily Price" shall be the price based on the VWAP of the Company on the Nasdaq SmallCap
Market or, if the Nasdaq SmallCap Market is not the Principal Market, on the Principal Market.
(b) "Draw Down" shall have the meaning assigned to such term in Section 6.1(a) hereof.
(c) "Draw Down Exercise Date" shall have the meaning assigned to such term in Section 6.1(b) hereof.
(d) "Draw Down Pricing Period" shall mean a period of twenty-two (22) consecutive Trading Days preceding a
Draw Down Exercise Date.
(e) "Effective Date" shall mean the date the Registration Statement of the Company covering the Shares being
subscribed for hereby is declared effective.
(f) "Material Adverse Effect" shall mean any adverse effect on the business, operations, properties or financial
condition of the Company that materially impairs the ability of the Company and its subsidiaries and affiliates,
taken as a whole, to perform any of its material obligations under this Agreement or to carry on its obligations,
and shall include the loss for any reason to the Company of the services of Dr. Paul Averback.
(g) "Principal Market" shall mean initially the Nasdaq SmallCap Market, and shall include the Nasdaq National
Market, the American Stock Exchange or the New York Stock Exchange if the Company is listed and trades on
such market or exchange, but shall not include the Montreal Stock Exchange.
(h) "Registration Statement" shall mean the registration statement under the Securities Act of 1933, as amended,
to be filed with the Securities and Exchange Commission for the registration of the Shares pursuant to the
Registration Rights Agre